Press Release: Travere Therapeutics to Report First Quarter 2024 Financial Results

Travere Therapeutics to Report First Quarter 2024 Financial Results SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report firs

Dow JonesApr 30 04:30

Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 25 02:48

Travere Therapeutics Price Target Raised to $19.00/Share From $17.00 by HC Wainwright & Co.

Travere Therapeutics Price Target Raised to $19.00/Share From $17.00 by HC Wainwright & Co.

Dow JonesApr 25 02:48

HC Wainwright & Co. : Travere Therapeutics (TVTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $19.00.

HC Wainwright & Co. : Travere Therapeutics (TVTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $19.00.

Zhitong FinanceApr 25 02:40

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $17 to $19.

BenzingaApr 25 02:38

Travere, CSL Win Conditional Nod for Kidney Disease Therapy in EU

Seeking AlphaApr 24 20:31